Natco seeks emergency approval in India for investigational therapy molnupiravir, currently being developed by Merck & Co for the treatment of non-hospitalized COVID-19 patients. The firm has linked its request to compassionate use amid a ferocious surge in COVID-19 cases in India, posing a potentially delicate choice for the regulator.
The Indian company Natco Pharma Limited has created a flutter in seeking an emergency go-ahead in India for molnupiravir, an investigational antiviral being pursued by Merck & Co., Inc. for the treatment of COVID-19.
Natco’s move is seen as combative by some given that Merck doesn’t appear to have partnered with the Indian firm...
Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.
Green light follows a recent rejection by the US FDA to partner Regeneron's request for an extension to the dosing interval.
Recent moves in the industry include C-suite changes at Atalanta Therapeutics and Climb Bio, plus seven companies get new CMOs.
